EER | ENST | ENSG | GeneName | Region | Repeat | dsRNA structure | chr17:80415974-80417078:+ | ENST00000520537.1 | ENSG00000173818.15 | ENDOV | ncRNA_exonic | L2b,AluSp,AluJo,(CCCT)n | chr17:80415974-80417078:+.alignment |
chr17:80415974-80417078:+ | ENST00000523165.1 | ENSG00000173818.15 | ENDOV | ncRNA_exonic | L2b,AluSp,AluJo,(CCCT)n | chr17:80415974-80417078:+.alignment |
chr17:80434658-80435989:+ | ENST00000517795.4 | ENSG00000173818.15 | ENDOV | intronic | L1MB7,AluY,AluJb | chr17:80434658-80435989:+.alignment |
chr17:80434658-80435989:+ | ENST00000518137.4 | ENSG00000173818.15 | ENDOV | intronic | L1MB7,AluY,AluJb | chr17:80434658-80435989:+.alignment |
chr17:80434658-80435989:+ | ENST00000518901.4 | ENSG00000173818.15 | ENDOV | intronic | L1MB7,AluY,AluJb | chr17:80434658-80435989:+.alignment |
chr17:80434658-80435989:+ | ENST00000518907.4 | ENSG00000173818.15 | ENDOV | intronic | L1MB7,AluY,AluJb | chr17:80434658-80435989:+.alignment |
chr17:80434658-80435989:+ | ENST00000520284.4 | ENSG00000173818.15 | ENDOV | intronic | L1MB7,AluY,AluJb | chr17:80434658-80435989:+.alignment |
chr17:80434658-80435989:+ | ENST00000520367.4 | ENSG00000173818.15 | ENDOV | intronic | L1MB7,AluY,AluJb | chr17:80434658-80435989:+.alignment |
ID_events | cancer | TypeID | ImmuneCell | P | R | CorrelationPlot |
chr17:80415974-80417078:+ | BLCA | EER | Dendritic_cells_resting | 4.4634e-02 | -0.2342 |  |
ENSG00000173818.15,ENDOV | BLCA | EAG | Dendritic_cells_resting | 4.4634e-02 | -0.2342 |  |
chr17:80415974-80417078:+ | BRCA | EER | T_cells_CD8 | 2.4685e-02 | -0.1364 |  |
ENSG00000173818.15,ENDOV | BRCA | EAG | T_cells_CD8 | 2.6833e-02 | -0.1333 |  |
ENSG00000173818.15,ENDOV | CESC | EAG | Dendritic_cells_activated | 7.2108e-03 | 0.4882 |  |
ENSG00000173818.15,ENDOV | COAD | EAG | T_cells_CD4_memory_resting | 6.1858e-03 | 0.4736 |  |
chr17:80415974-80417078:+ | ESCA | EER | Macrophages_M1 | 9.5185e-03 | 0.2419 |  |
ENSG00000173818.15,ENDOV | ESCA | EAG | Macrophages_M1 | 9.5185e-03 | 0.2419 |  |
chr17:80415974-80417078:+ | GBM | EER | T_cells_CD4_memory_activated | 7.4193e-05 | 0.3971 |  |
ENSG00000173818.15,ENDOV | GBM | EAG | T_cells_CD4_memory_activated | 7.4193e-05 | 0.3971 |  |
chr17:80415974-80417078:+ | KIRC | EER | T_cells_CD8 | 2.3401e-02 | 0.2211 |  |
ENSG00000173818.15,ENDOV | KIRC | EAG | T_cells_CD8 | 2.7656e-02 | 0.2150 |  |
chr17:80415974-80417078:+ | KIRP | EER | Neutrophils | 1.3282e-03 | 0.3263 |  |
ENSG00000173818.15,ENDOV | KIRP | EAG | Neutrophils | 1.3282e-03 | 0.3263 |  |
chr17:80415974-80417078:+ | LGG | EER | Plasma_cells | 7.5373e-03 | 0.1496 |  |
ENSG00000173818.15,ENDOV | LGG | EAG | Plasma_cells | 7.5372e-03 | 0.1496 |  |
ENSG00000173818.15,ENDOV | LUAD | EAG | T_cells_regulatory_(Tregs) | 3.8574e-02 | 0.2478 | .ENSG00000173818.15,ENDOV.png) |
chr17:80415974-80417078:+ | LUSC | EER | Neutrophils | 3.7851e-02 | -0.2298 |  |
ENSG00000173818.15,ENDOV | LUSC | EAG | Neutrophils | 3.7851e-02 | -0.2298 |  |
chr17:80415974-80417078:+ | PRAD | EER | NK_cells_activated | 1.2761e-02 | -0.1990 |  |
ENSG00000173818.15,ENDOV | PRAD | EAG | NK_cells_activated | 7.8683e-03 | -0.2114 |  |
chr17:80415974-80417078:+ | SARC | EER | Monocytes | 3.3130e-02 | 0.3776 |  |
ENSG00000173818.15,ENDOV | SARC | EAG | Monocytes | 3.3130e-02 | 0.3776 |  |
chr17:80415974-80417078:+ | SKCM | EER | T_cells_CD4_memory_resting | 3.8191e-03 | 0.3622 |  |
ENSG00000173818.15,ENDOV | SKCM | EAG | T_cells_CD4_memory_resting | 3.8191e-03 | 0.3622 |  |
chr17:80415974-80417078:+ | THCA | EER | Dendritic_cells_activated | 3.8519e-02 | 0.1176 |  |
ENSG00000173818.15,ENDOV | THCA | EAG | Dendritic_cells_activated | 3.8519e-02 | 0.1176 |  |
ID_events | cancer | HallmarkType | Type | P | R | CorrelationPlot |
ENSG00000173818.15,ENDOV | BLCA | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EAG | 1.6317e-02 | -0.2784 |  |
chr17:80415974-80417078:+ | BLCA | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EER | 1.6317e-02 | -0.2784 |  |
ENSG00000173818.15,ENDOV | BRCA | GSVA_HALLMARK_GLYCOLYSIS | EAG | 8.3214e-04 | 0.2000 |  |
chr17:80415974-80417078:+ | BRCA | GSVA_HALLMARK_GLYCOLYSIS | EER | 5.6104e-04 | 0.2082 |  |
ENSG00000173818.15,ENDOV | CESC | GSVA_HALLMARK_GLYCOLYSIS | EAG | 7.3801e-03 | 0.4870 |  |
ENSG00000173818.15,ENDOV | GBM | GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE | EAG | 4.1565e-02 | 0.2106 |  |
chr17:80415974-80417078:+ | GBM | GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE | EER | 4.1565e-02 | 0.2106 |  |
chr17:80415974-80417078:+ | KIRC | GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE | EER | 4.7917e-03 | 0.2733 |  |
ENSG00000173818.15,ENDOV | KIRC | GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE | EAG | 5.1368e-03 | 0.2712 |  |
ENSG00000173818.15,ENDOV | LAML | GSVA_HALLMARK_MITOTIC_SPINDLE | EAG | 1.8401e-03 | 0.4038 |  |
chr17:80415974-80417078:+ | LAML | GSVA_HALLMARK_MITOTIC_SPINDLE | EER | 1.9116e-03 | 0.4059 |  |
chr17:80415974-80417078:+ | LUAD | GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS | EER | 9.7192e-03 | -0.3138 |  |
chr17:80415974-80417078:+ | LUSC | GSVA_HALLMARK_MITOTIC_SPINDLE | EER | 8.0174e-03 | 0.2909 |  |
ENSG00000173818.15,ENDOV | LUSC | GSVA_HALLMARK_MITOTIC_SPINDLE | EAG | 8.0174e-03 | 0.2909 |  |
chr17:80415974-80417078:+ | OV | GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS | EER | 1.6314e-03 | 0.2002 |  |
ENSG00000173818.15,ENDOV | OV | GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS | EAG | 1.6775e-03 | 0.1997 |  |
chr17:80415974-80417078:+ | PCPG | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION | EER | 4.2158e-02 | -0.2509 |  |
ENSG00000173818.15,ENDOV | PCPG | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION | EAG | 4.2158e-02 | -0.2509 |  |
chr17:80415974-80417078:+ | PRAD | GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE | EER | 2.8826e-02 | 0.1751 |  |
ENSG00000173818.15,ENDOV | PRAD | GSVA_HALLMARK_PEROXISOME | EAG | 3.2568e-02 | 0.1707 |  |
chr17:80415974-80417078:+ | SARC | GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE | EER | 1.3861e-02 | 0.4307 |  |
ENSG00000173818.15,ENDOV | SARC | GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE | EAG | 1.3861e-02 | 0.4307 |  |
chr17:80415974-80417078:+ | SKCM | GSVA_HALLMARK_P53_PATHWAY | EER | 1.4868e-02 | 0.3080 |  |
ENSG00000173818.15,ENDOV | SKCM | GSVA_HALLMARK_P53_PATHWAY | EAG | 1.4868e-02 | 0.3080 |  |
chr17:80415974-80417078:+ | STAD | GSVA_HALLMARK_ANDROGEN_RESPONSE | EER | 5.1729e-04 | 0.2332 |  |
ENSG00000173818.15,ENDOV | STAD | GSVA_HALLMARK_ANDROGEN_RESPONSE | EAG | 5.6032e-04 | 0.2318 |  |
ENSG00000173818.15,ENDOV | THCA | GSVA_HALLMARK_GLYCOLYSIS | EAG | 2.0898e-03 | 0.1741 |  |
chr17:80415974-80417078:+ | THCA | GSVA_HALLMARK_GLYCOLYSIS | EER | 2.0898e-03 | 0.1741 |  |
ENSG00000173818.15,ENDOV | UCEC | GSVA_HALLMARK_MTORC1_SIGNALING | EAG | 1.0624e-04 | 0.6869 |  |
chr17:80415974-80417078:+ | UCEC | GSVA_HALLMARK_MTORC1_SIGNALING | EER | 1.0624e-04 | 0.6869 |  |
ID_events | cancer | Drug | Type | P | R | CorrelationPlot |
ENSG00000173818.15,ENDOV | BLCA | Erlotinib | EAG | 1.1316e-02 | 0.2929 |  |
chr17:80415974-80417078:+ | BLCA | Erlotinib | EER | 1.1316e-02 | 0.2929 |  |
ENSG00000173818.15,ENDOV | BRCA | FH535 | EAG | 3.0944e-02 | -0.1299 |  |
chr17:80415974-80417078:+ | BRCA | Bosutinib | EER | 3.2225e-02 | 0.1304 |  |
ENSG00000173818.15,ENDOV | CESC | BMS.708163 | EAG | 4.7885e-04 | 0.6071 |  |
ENSG00000173818.15,ENDOV | GBM | Cisplatin | EAG | 4.5208e-02 | -0.2071 |  |
chr17:80415974-80417078:+ | GBM | Cisplatin | EER | 4.5208e-02 | -0.2071 |  |
chr17:80415974-80417078:+ | KIRC | AZD.2281 | EER | 1.0473e-03 | -0.3154 |  |
ENSG00000173818.15,ENDOV | KIRC | AZD.2281 | EAG | 1.0957e-03 | -0.3143 |  |
ENSG00000173818.15,ENDOV | KIRP | CGP.082996 | EAG | 2.7285e-02 | -0.2277 |  |
chr17:80415974-80417078:+ | KIRP | CGP.082996 | EER | 2.7285e-02 | -0.2277 |  |
ENSG00000173818.15,ENDOV | LAML | AZD6482 | EAG | 1.8256e-02 | -0.3117 |  |
chr17:80415974-80417078:+ | LAML | AZD6482 | EER | 1.8755e-02 | -0.3132 |  |
ENSG00000173818.15,ENDOV | LGG | BX.795 | EAG | 2.1965e-02 | 0.1284 |  |
chr17:80415974-80417078:+ | LGG | BX.795 | EER | 2.1967e-02 | 0.1284 |  |
chr17:80415974-80417078:+ | LUAD | GDC0941 | EER | 1.6803e-02 | -0.2912 |  |
ENSG00000173818.15,ENDOV | LUAD | GDC0941 | EAG | 1.9060e-02 | -0.2796 |  |
chr17:80415974-80417078:+ | OV | Lapatinib | EER | 5.9406e-03 | -0.1753 |  |
ENSG00000173818.15,ENDOV | OV | Lapatinib | EAG | 6.2542e-03 | -0.1742 |  |
chr17:80415974-80417078:+ | PCPG | AZD6482 | EER | 9.4098e-04 | -0.3978 |  |
ENSG00000173818.15,ENDOV | PCPG | AZD6482 | EAG | 9.4098e-04 | -0.3978 |  |
chr17:80415974-80417078:+ | PRAD | Lapatinib | EER | 7.5986e-03 | -0.2130 |  |
ENSG00000173818.15,ENDOV | PRAD | Lapatinib | EAG | 4.6092e-03 | -0.2250 |  |
chr17:80415974-80417078:+ | SARC | CCT018159 | EER | 1.8852e-02 | -0.4129 |  |
ENSG00000173818.15,ENDOV | SARC | CCT018159 | EAG | 1.8852e-02 | -0.4129 |  |
chr17:80415974-80417078:+ | STAD | FTI.277 | EER | 1.4082e-02 | -0.1661 |  |
ENSG00000173818.15,ENDOV | STAD | FTI.277 | EAG | 1.4965e-02 | -0.1646 |  |
ENSG00000173818.15,ENDOV | THCA | ABT.263 | EAG | 2.7352e-05 | 0.2358 |  |
chr17:80415974-80417078:+ | THCA | ABT.263 | EER | 2.7352e-05 | 0.2358 |  |
ENSG00000173818.15,ENDOV | UCEC | Gefitinib | EAG | 9.3652e-03 | 0.4996 |  |
chr17:80415974-80417078:+ | UCEC | Gefitinib | EER | 9.3652e-03 | 0.4996 |  |